Over half of postpartum women suffer from melasma. Our transdermal delivery system delivers significant and fast reduction in pigmentation with results that meet or exceed current treatment options. Learn more: dyvebio.com #biotech #aesthetic #bioinvestor #investor

Dyve Biosciences will be in Boston next week for #PODD2019. CEO Ryan Beal, MD will be presenting on the power and potential of Dyve’s transdermal drug delivery technology on October 7th at 5:00pm (Track 2A). Learn more: dyvebio.com

Dyve CEO Ryan Beal, M.D. will be presenting at Bio Investor Forum next week in San Fran. Topic is "Reimagining transdermal drug delivery: subcutaneous injections in a topical cream" Tuesday, October 22nd 9:00 AM The Westin St. Francis, Elizabethan B #BIO19 #BioInvestor

Great energy this morning at #BIO19. Dyve CEO Ryan Beal MD speaking to "Reimagining Transdermal Drug Delivery".

Look for us in Atlanta this weekend for #acr19! Dyve's Scientific Advisory Board member Smitha Reddy, MD will be presenting in Hall B5 on the observed efficacy and safety of Dyve's technology applied to relieve pain associated with acute #gout flares.

Dyve's SAB member Smitha Reddy, MD with CEO Ryan Beal, MD before Dr. Reddy's poster presentation at #ACR19 in Atlanta. For the complete poster, visit our publications page on our website: dyvebio.com/newsroom/publi…

When should lasers be used to treat #melasma? Mildred López Piñeiro, M.D. provides her insight in our new column on energy devices. buff.ly/2QqsUeJ

CEO Ryan Beal, MD chatted with Modern Aesthetics about the latest research on Dyve's technology. Check out the full article: bit.ly/2OugRKK

DYV-700 was recently approved for phase 2 trial for treatment of acute gout pain. Here's why we're excited.

.Dyve Biosciences wins FDA nod for Phase 2 transdermal drug delivery trial bit.ly/2PpPnYc

Gout flares are characterized by the formation of sodium urate crystals in the joint space, causing intense pain typically lasting 48-96 hours.

Dyve is thrilled to welcome longtime Pfizer Executive Chuck Harbert, Ph.D. to the company in the role of Chief Scientific Officer. Full press release: tinyurl.com/yexnmx99 Learn more about Dyve: dyvebio.com

BIO is helping leaders fulfill that commitment by providing resources to help build a more inclusive and diverse workforce. Learn more at buff.ly/2S3JkIT #rightmixmatters

Thanks to @byndergroup for their continued partnership and the amazing work they've put into developing our website! dyvebio.com

We had an exciting week in New York! Thank you to Biotechnology Innovation Organization for hosting #BIOCEO20 as well as Nasdaq for highlighting Dyve on #NasdaqSpotlight! #biotech

First subjects were enrolled in Dyve's Phase 2 TARGETS study this week! Thank you to all of our partners for making this achievement possible. It is an exciting milestone for our company! #gout #biotech

Thank you Josh Machiz and Nasdaq for featuring Dyve in their #NasdaqSpotlight series in New York City last week! You can view the full interview with CEO Ryan Beal on Dyve's website: bit.ly/38LLx2M #biotech #healthcare

Thank you to MassDevice for highlighting Dyve's press release announcing first patient enrollment in Phase 2 TARGETS Study for Acute Gout: bit.ly/2PcQfiu #gout #biotech #clinicaltrials

Dyve’s science has demonstrated the power to deliver up to 40% of the applied dose into the blood, which exceeds what is seen by many pills. #biotech